Check out the latest news and information from the Foundation by liking us on Facebook!
This year's Annual T-cell Lymphoma Forum focused on the latest findings in T-cell lymphoma including: global epidemiology, prognostic markers and tools, pathobiology, clincial management and global implications. In addition to 47 individual presentations, there were many posters on display; approximately half of which related specifically to cutaneous lymphoma.
The CLF's Susan Thornton attended the Forum on behalf of the Foundation. Click here to read her highlights from the Forum.
(Note: At the time the T-Cell Forum highlights were written, brentuximab vedotin was in Phase II testing. Currently it is in Phase III testing. Visit the clinical trials page to learn more.)
January 23, 2014 - To help consumers understand their out-of-pocket health care costs as they shop for a marketplace plan, the National Health Council (NHC) has launched PuttingPatientsFirst.net, an interactive web-based suite of resources.
PuttingPatientsFirst.net is a unique platform that seeks to make consumers more informed about expected health care costs in the marketplace using a personalized out-of-pocket cost estimator and patient scenarios that explain how an individual's costs can vary under different health insurnace plan designs.
Click here to read the full press release.
Click here to download the Putting Patients First fact sheet.
Click here to download the Putting Patients First infographic.
Medicis, a division of Valeant Pharmaceuticals, recently introduced the Targretin® Patient Care Program. The program represents Medicis’ commitment to helping refractory cutaneous T-cell lymphoma CTCL patients who have been prescribed Targretin (bexarotene) Capsules or Targretin (bexarotene) Gel gain access to medication and to the support they need to move forward with understanding and managing their disease. This program assists with the complex financial coordination Targretin Capsules or Targretin Gel can require and provides patient follow-up to encourage therapy adherence. With the new rebate program, eligible commercially insured patients’ co-pays are no more than $20. Patients with no commercial insurance or with government insurance, such as Medicare Part D may still be eligible for alternative financial assistance, if needed. Patients should call 1-888-479-6337 to gain additional information including the full terms and conditions of the Patient Care Program.
Please see www.targretin.com for Full Prescribing Information, including Pregnancy Boxed Warning.